H.C. Wainwright analyst Andres Y. Maldonado has reiterated their bullish stance on TCRX stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight TScan Therapeutics’ strategic advancements in both hematologic and solid tumor programs. The company’s TSC-101 trial is on track to begin in the second half of 2025, with promising two-year relapse data from the ALLOHA Phase 1 study expected by the end of 2025. Additionally, the introduction of multiplex TCR-T therapy in solid tumors is set to commence in the third quarter, with early safety and response data anticipated in the first quarter of 2026.
The persistence of engineered T cells beyond one year, complete MRD clearance, and full donor chimerism in ALLOHA patients suggest potential for durable disease control. The incorporation of DN-TGFβRII and CD8α/β co-expression in the multiplex construct addresses previous challenges in TCR-T trials, enhancing the platform’s competitive differentiation. Furthermore, the synthetic control arm design could expedite trial timelines, positioning TScan to address a broader oncology population compared to existing therapies.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as Merus, ImmunityBio, and I-MAB. According to TipRanks, Y. Maldonado has an average return of 6.5% and a 45.04% success rate on recommended stocks.
In another report released on August 13, Barclays also maintained a Buy rating on the stock with a $3.00 price target.